-
INOpulse’s positive effects on PH-COPD to be presented
Bellerophon‘s positive top-line results from its Phase 2 trial testing INOpulse as a potential therapy for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) will be presented at an upcoming conference, the company announced. Results of the trial, which were initially announced in September 2017, showed that INOpulse, a portable device that delivers a vasodilator gas called nitric oxide, or iNO, improved blood flow and increased patients’ exercise capacity.
Patients can use the device daily, either at home or elsewhere. Findings from the trial will be presented at he American Thoracic Society 114th International Conference on May 21 in San Diego. Click here to read more: #ATS2018 — Bellerophon Presenting Top-line Results Showing INOpulse’s Benefits in PH-COPD Patients
Are you familiar with INOpulse therapy? What are your thoughts on this news?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.